Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
Geneart AG (OJ:G6A) - GENEART increases sales activities in its key foreign market - Founding of a new sales office in San Francisco (California, USA) is completed - GENEART positions itself in the vicinity of customers on the west coast, with research budgets of more than USD 12 billion
Regensburg, September 8, 2008 - GENEART AG, the global leader in gene synthesis and specialist in the field of Synthetic Biology, has announced the founding of a new subsidiary on the west coast of the USA in San Francisco, California. The newly-founded subsidiary GENEART Inc. is located in the San Francisco Bay Area, at the heart of one of the largest biotech clusters in the world. More than 140 listed biotechnology companies in California generate annual sales of approximately USD 44 billion and spend more than USD 12 billion on research and development.* In addition to the large number of biopharmaceutical/biotechnology firms and large research centers, numerous renowned academic research institutions along the west coast of the U.S. are working on the development of new industrial products and therapeutics. "With our two subsidiaries in Toronto, Canada and San Francisco, U.S., we can now offer optimum support for the largest biotechnology research clusters in North America. This benefits all researchers in the pharmaceutical and biotechnology industries as well as academic institutions working on the development of innovative biopharmaceuticals, vaccines and industrial enzymes. Direct contact to our customers and outstanding customer service are key factors for continued strong growth in North America, our most important foreign market," says Christian Ehl, CEO of GENEART AG.
Frank Ostermair Better Orange IR & HV AG Haidelweg 48 81241 Munich Germany Phone: +49-(0)89-8896906-10 Fax: +49-(0)89-8896906-66 info@better-orange.de www.better-orange.de
Legal Information This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results.
About GENEART AG In 2000, GENEART entered the gene synthesis market and has since become the global market leader. Today, the company is one of the leading specialists in the Synthetic Biology field. Experts at GENEART provide key technologies for the development and production of new therapeutics and vaccines. Customers also take advantage of GENEART services to customize enzyme attributes, such as the attributes of enzymes used as detergent additives, and to construct bacteria, which produce complex biopolymers or break down polymers, such as synthetics, petroleum components, etc. Our production and service spectrum spans a wide range, from the production of synthetic genes according to DIN EN ISO 9001-2000, to the creation of gene libraries in the combinatorial biology, to the development and production of DNA-based biologically active substances. The GENEART AG in Regensburg (Germany) and the subsidiary GENEART Inc. in Toronto (Canada) employ more than 190 people. Since May 2006, GENEART is listed on the German Stock Exchange.
